10:01 AM EST - Cardiol Therapeutics Inc. : Added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study topline results. The Canadian biotechnology company has captured investors’ attention this year with significant milestones achieved, including the advancement of two simultaneous Phase II clinical trials, granting of Orphan Drug Designation by the US FDA for its flagship drug CardiolRx™, and most recently, the announcement of positive topline results from their MAvERIC-Pilot study. Cardiol Therapeutics Inc.
shares T.CRDL are trading down $0.04 at $3.24.
